Global Lenalidomide Market to Reach USD 20.85 Billion by 2031, Advancing at a 5.39% CAGR
Dublin, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The "Lenalidomide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Global Lenalidomide Market to Reach USD 20.85 Billion by 2031, Advancing at a 5.39% CAGR
The global lenalidomide market is estimated at USD 16.03 billion in 2026, up from USD 15.21 billion in 2025. The market is projected to reach USD 20.85 billion by 2031, registering a compound annual growth rate of 5.39% from 2026 to 2031. Growth is supported by the rising incidence of multiple myeloma and related hematologic malignancies, expanding treatment indications, longer maintenance therapy durations, and wider access to generic lenalidomide.
Rising Multiple Myeloma Incidence Supports Lenalidomide Market Growth
The increasing prevalence of plasma-cell malignancies among aging populations continues to sustain demand for lenalidomide-based treatment. In North America and Europe, updated clinical guidelines support continuous maintenance therapy as a central component of early-line multiple myeloma management. This approach extends treatment duration, with many eligible patients remaining on therapy for more than 24 months when treatment is tolerated.
Growing geriatric populations are also increasing the need for flexible treatment strategies. Dose optimization is becoming more important for older, frail, or renal-impaired patients, encouraging demand across several dosage strengths. Although the 25 mg capsule accounted for 34.83% of market revenue in 2025, physicians are increasingly using 15 mg, 10 mg, 5 mg, and 2.5 mg formulations during maintenance therapy or for patients requiring dose adjustments.
Expanded Indications and Combination Regimens Strengthen Demand
Broader regulatory approvals have expanded lenalidomide use beyond multiple myeloma into mantle cell lymphoma and selected lymphomas that relapse following anti-CD20 treatment. In 2024, the U.S. Food and Drug Administration approved isatuximab in combination with lenalidomide for transplant-ineligible multiple myeloma, reinforcing the drug's role in combination treatment protocols.
Lenalidomide is also increasingly incorporated into standard triplet and quadruplet regimens. These combinations support its continued use in frontline treatment and maintenance care, while ongoing clinical research in additional hematologic malignancies could further diversify demand.
Multiple Myeloma Remains the Leading Application
Multiple myeloma represented 59.72% of lenalidomide market revenue in 2025 and is expected to remain the leading application through 2031. Frontline induction protocols and extended maintenance regimens continue to support prescription volumes. Mantle cell lymphoma is forecast to grow at a 5.93% CAGR through 2031 as studies involving combinations with rituximab and ibrutinib progress into clinical practice.
Demand also remains resilient in del(5q) myelodysplastic syndromes, where real-world evidence continues to demonstrate meaningful hematologic responses. However, newer treatment classes, including next-generation cereblon E3 ligase modulators and bispecific antibodies, may compete for overlapping patient populations.
Generic Lenalidomide Improves Affordability and Access
The availability of generic lenalidomide is reducing treatment costs and supporting wider access, particularly through public procurement programs and hospital tenders. Manufacturers offering a broad range of dosage strengths are well positioned to address the growing emphasis on individualized dosing. Lower-strength capsules are expected to expand faster than the overall market as clinicians prioritize tolerability during long-term therapy.
Despite these opportunities, safety requirements remain a significant market restraint. Lenalidomide's teratogenic risk requires strict Risk Evaluation and Mitigation Strategy compliance, including pregnancy testing, patient counseling, and controlled dispensing. Treatment-related cytopenias and fatigue can also lead to discontinuation, creating additional challenges for healthcare providers and community oncology clinics.
Regional Lenalidomide Market Outlook
North America held 40.35% of global revenue in 2025, supported by broad insurance coverage and the early adoption of advanced combination regimens. Changes to Medicare Part D formularies may accelerate conversion from branded Revlimid to lower-cost generic alternatives, while future pricing negotiations could strengthen volume growth under value-based care models.
Asia-Pacific is forecast to record the fastest regional growth, with a 6.28% CAGR through 2031. China's approval of first-line lenalidomide regimens and expanded provincial reimbursement are expected to increase patient access. India benefits from integrated active pharmaceutical ingredient production and competitive public hospital pricing, while Japan's aging population and adoption of oral combination therapies continue to support demand.
Europe is expected to maintain mid-single-digit growth. Generic launches have driven rapid conversion from branded products, with centralized procurement systems generating savings while preserving treatment access. Supply-chain oversight will remain important as regional buyers monitor active pharmaceutical ingredient sourcing and potential export-related disruptions.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising global incidence of multiple myeloma & related blood cancers
4.2.2 Expanding label indications, including lymphomas, maintenance therapy
4.2.3 Availability of generics driving affordability, wider access
4.2.4 Integration into standard triplet/quadruplet treatment regimens
4.2.5 Tele-oncology & e-pharmacy channels expanding REMS-drug reach
4.2.6 Patient-assistance & donation programs in LMICs accelerating uptake
4.3 Market Restraints
4.3.1 Severe side-effects & stringent REMS compliance burden
4.3.2 Price erosion & revenue dilution post-patent-expiry
4.3.3 API supply-chain bottlenecks causing periodic shortages
4.3.4 Next-gen CELMoDs & bispecifics cannibalising demand
4.4 Regulatory Landscape
4.5 Porters Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Application
5.1.1 Multiple Myeloma
5.1.2 Myelodysplastic Syndromes (MDS)
5.1.3 Mantle Cell Lymphoma
5.1.4 Follicular & Marginal-Zone Lymphoma
5.1.5 Chronic Lymphocytic Leukemia
5.1.6 Other Applications
5.2 By Dosage Strength
5.2.1 2.5 mg
5.2.2 5 mg
5.2.3 10 mg
5.2.4 15 mg
5.2.5 25 mg
5.2.6 Others
5.3 By Age Group
5.3.1 Adults
5.3.2 Geriatric
5.3.3 Pediatric
5.4 By Distribution Channel
5.4.1 Hospital Pharmacies
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Russia
5.5.2.7 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Bristol-Myers Squibb Company
6.3.2 Teva Pharmaceutical Industries
6.3.3 Dr. Reddy's Laboratories
6.3.4 Cipla Ltd
6.3.5 Sandoz
6.3.6 Natco Pharma
6.3.7 Hetero Healthcare
6.3.8 Amneal Pharmaceuticals
6.3.9 Apotex Inc
6.3.10 Reliance Life Sciences
6.3.11 Synthon
6.3.12 Deva Holding
6.3.13 Delphis Pharma
6.3.14 Accord Healthcare
6.3.15 Sun Pharmaceutical Industries
6.3.16 Viatris Inc.
6.3.17 Lupin Limited
6.3.18 Zydus Lifesciences
6.3.19 Glenmark Pharmaceuticals
6.3.20 Intas Pharmaceuticals
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/uczd08
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.